

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61L 15/18</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/38735 (43) International Publication Date: 23 October 1997 (23.10.97)</p>
<p>(21) International Application Number: PCT/US97/05848 (22) International Filing Date: 10 April 1997 (10.04.97) (30) Priority Data: 08/631,119 12 April 1996 (12.04.96) US (71) Applicant: ENVIRODERM PHARMACEUTICALS, INC. [US/US]; 1600 West Hill Street, Louisville, KY 40210 (US). (72) Inventor: SCHULZ, Anthony, A.; 3714 Flemar Drive, Floyds Knobs, IN 47119 (US). (74) Agent: BOLAND, Thomas, R.; Vorys, Sater, Seymour and Pease, Suite 1111, 1828 L Street, N.W., Washington, DC 20036-5104 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: METHOD OF PREVENTING SKIN IRRITATION CAUSED BY FECAL ENZYMES</p>		
<p>(57) Abstract</p> <p>Skin irritation, such as diaper rash, appearing when the skin is allowed to remain in contact with proteolytic enzymes found in feces is prevented by inactivating the fecal proteolytic enzymes by contact with organophilic clays. The organophilic clays are applied to the skin in areas likely to come into contact with feces or to garments such as diapers. A composition suitable for practicing the method of the invention comprises an amount of an organophilic clay effective to inactivate irritating fecal proteolytic enzymes dispersed in a pharmaceutically acceptable non-toxic dermatological vehicle. A fabric incorporating organophilic clay, preferably dispersed in a matrix of a superabsorbent polymer, is useful for preparing diapers for infants that can help to prevent skin irritation by fecal enzymes.</p> <p style="text-align: center; font-size: 2em; font-weight: bold;">BEST AVAILABLE COPY</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BEST AVAILABLE COPY

TITLE: METHOD OF PREVENTING SKIN IRRITATION CAUSED BY
FECAL ENZYMES

5

BACKGROUND OF THE INVENTION

Field of the invention:

This invention relates to methods of prevention of skin
irritation such as diaper rash and more particularly to
10 prevention and treatment of diaper rash caused by fecal
enzymes.

Brief description of the prior art:

Diaper rash is a form of contact dermatitis which
afflicts infants whose wet and/or soiled diapers are not
15 promptly changed. Because of the practical impossibility of
attending promptly to all of an infant's needs, even those
infants receiving a high level of care sometimes suffer from
diaper rash.

It has recently come to be understood that the initial
20 stages of some types of diaper rash are the result of skin
irritation caused by contact with digestive enzymes present
in infant feces, particularly trypsin, chymotrypsin and
elastase. These enzymes are proteolytic enzymes produced in
the gastrointestinal tract to digest food. In infants, the
25 feces tend to be watery and they contain, among other
materials such as bacteria, some amounts of undegraded
digestive enzymes. These enzymes, if they remain in contact
with the skin for any appreciable period of time have been
found to cause an irritation that is uncomfortable in itself
30 and can predispose the skin to infection by microorganisms.

Conventional methods of preventing or alleviating diaper
rash have included application of powders to keep the skin
dry and creams and ointments to protect the skin from contact
with irritants. However diaper rash continues to be a
35 problem for infants and parents.

Similar conditions conducive to skin irritation by proteolytic enzymes present in feces are found in patients having colostomies and the like. Such patients also would benefit from improved treatments to prevent skin irritation due to fecal enzymes.

Accordingly, a need has continued to exist for additional methods of preventing and treating diaper rash and similar skin irritations.

SUMMARY OF THE INVENTION

The need for additional methods of preventing diaper rash has now been met by the method of this invention wherein fecal proteolytic enzymes are inactivated by contact with organophilic clays. A composition suitable for practicing the method of the invention comprises an amount of an organophilic clay effective to inactivate irritating fecal proteolytic enzymes dispersed in a pharmaceutically acceptable non-toxic dermatological vehicle.

In a further embodiment of the invention a composition containing organophilic clay, e.g, a superabsorbent polymer containing an organophilic clay, is incorporated into a fabric that is used to make garments, such as diapers, that may come into contact with feces containing skin-irritating enzymes.

Accordingly, it is an object of the invention to provide a method for preventing diaper rash.

A further object is to prevent contact dermatitis due to fecal enzymes.

A further object is to provide a composition for application to the skin that can prevent diaper rash.

A further object is to provide a composition for application to the skin that can prevent contact dermatitis due to proteolytic enzymes such as those present in feces.

A further object is to provide a method of inactivating skin-irritating fecal enzymes.

A further object is to provide a composition capable of inactivating skin-irritating fecal enzymes.

A further object is to provide a composition capable of inactivating skin-irritating fecal enzymes that can be incorporated into a fabric.

5 A further object is to provide a fabric incorporating a composition that is capable of inactivating skin-irritating fecal enzymes.

A further object is to provide a garment such as a diaper incorporating a composition that is capable of inactivating skin-irritating fecal enzymes.

10 Other objects of the invention will become apparent from the description of the invention which follows.

DETAILED DESCRIPTION OF THE INVENTION
AND PREFERRED EMBODIMENTS

15 According to the method of the invention the irritating effects of fecal proteolytic enzymes are alleviated by contacting the enzymes with materials that inactivate the enzymes by adsorbing them or rendering them incapable of performing their native proteolytic activity. In particular, it has been found that organophilic clays can adsorb fecal
20 enzymes, thereby preventing them from contacting the skin, and also inactivate such enzymes, thereby rendering them incapable of causing irritation to the skin.

According to the method of the invention feces containing irritating proteolytic enzymes are contacted with
25 an amount of organophilic clay sufficient to reduce the activity of the enzymes and thereby decrease or eliminate their ability to cause irritation to the skin. In order to assure that the organophilic clay comes into contact with the proteolytic enzymes it is disposed in anatomical region
30 likely to be contacted by feces, e.g., by applying it to the skin in those areas generally covered by an infant's diaper or by applying it to the diaper itself or incorporating it into the structure of the diaper.

In a preferred embodiment the organophilic clay is
35 incorporated into a pharmaceutically acceptable skin coating material that is applied to the skin, e.g., of an infant, in

the region which is subject to contact with feces. The organophilic clay-containing medium is applied sufficiently frequently, e.g., after each diaper change, and in sufficient amount to maintain an effective amount of the organophilic clay associated with the skin where it can adsorb and deactivate the fecal enzymes.

The amount of organophilic clay applied to the skin is evidently not critical, provided that enough is used to produce a substantial decrease in the irritation caused by the fecal enzymes. Typically, the amount of organophilic clay applied to the skin will be at least 0.25 milligrams per square centimeter

The organophilic clay used in the method of the invention is typically applied to the skin in a dermatological composition comprising a suspension of the organophilic clay in a pharmaceutically acceptable vehicle. Suitable vehicles include organic and aqueous liquid vehicles, lotions, creams, emulsions, gels or the like. The organophilic clay can also be applied in finely divided form as a mixture with a dusting powder, e.g., as a mixture with a talcum powder or a finely divided starch powder.

The protective composition also may act as a barrier to prevent the fecal enzymes from coming into contact with the skin. The vehicle may contain emollients to aid in healing irritated skin and dispersants if necessary to keep the organophilic clay in suspension. The vehicle should preferably be inert with respect to the organophilic clay, i.e., it should be devoid of materials that will themselves adsorb to the organophilic clay and thereby deactivate the adsorptive or inactivating properties of the organophilic clay which are the basis for its ability to inactivate proteolytic fecal enzymes. In general, compounds having relatively long hydrocarbon chains, i.e., C-8 and longer, should be excluded from the protective composition because such hydrocarbon chains tend to interact with the

organophilic clay and reduce or destroy its adsorptive properties for proteolytic fecal enzymes.

Accordingly, a dermatological composition incorporating the organophilic clay for use in the method of this invention might incorporate from about 3 % to about 50 % by weight of organophilic clay in a conventional dermatological vehicle. Preferably, the composition comprises from about 3 % to about 20 % by weight and more preferably from about 5 % to about 10 % by weight.

Suitable vehicles include hydrophobic vehicles such as petrolatum or mineral oil or mixtures thereof, or hydrophilic vehicles such as aqueous-base creams including emulsions of petrolatum and/or mineral oil in water, and aqueous-based media thickened with viscosity-adjusting agents. Suitable thickening agents for aqueous-based vehicles include polyoxyethylenes, e.g., polyethylene glycols and derivatives having a molecular weight from about 3000 to about 20,000; polycarboxylic acids, e.g., polyacrylic acid and salts thereof; cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose sodium; and hydrophilic organic polymers such as poly(vinyl alcohol), poly(vinylpyrrolidone), poly(acrylic acid) sodium salt, and the like. Natural gums such as xanthan gum, carrageenan, gum tragacanth and the like are also useful as thickeners for aqueous-based vehicles. The thickener may also be a colloidal dispersion of a hydrophilic clay such as naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite, stevensite, or the like, and their synthetically produced analogs.

The dermatological composition incorporating an organophilic clay should have a viscosity sufficient to permit easy spreading on the skin and yet retain the active ingredient in a generally intact layer over the skin to be protected. Dermatological vehicles are well-known to the skilled practitioner and the selection and formulation of an

appropriate vehicle is within the capability of such a practitioner without undue experimentation.

The organophilic clay that comprises the barrier and/or fecal enzyme adsorbing and inactivating material in the protective compositions used in the method of this invention may be any conventional organophilic clay of commerce suitable for drug use. Such organophilic clays are well known and can be prepared from any of the clays of the smectite class that are known to swell in water and/or hydrophilic solvents to form viscous suspensions. Suitable clays include naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite and stevensite, and their synthetically made counterparts. These clays have a lamellar structure wherein alkali metal ions are distributed between the lamellae. Treatment of the clay with long-chain organic amphiphilic compounds such as long-chain quaternary amines results in exchange of the alkali metal ions by cationic organic molecules and thereby renders the clay organophilic.

The quaternary ammonium compounds used in preparing the organophilic clay component of the skin-protecting composition used in the method of the invention typically have one or two long-chain substituents, e.g., 14-20 carbon atoms, and two or three short-chain substituents such as methyl groups. A preferred quaternary ammonium compound is dimethyl dihydrogenated tallow ammonium chloride. Because the tallow contains a large proportion of stearic acid, which contains 18 carbon atoms, the resulting clay is often referred to as a quaternium 18 clay, e.g., quaternium 18 bentonite, or quaternium 18 hectorite. The composition and preparation of such organophilic clays is discussed in U.S. Patent 4,861,584. A preferred organophilic clay for use in the method of this invention is quaternium 18 bentonite.

The organophilic clay used in the method of this invention is preferably activated by thorough dispersion with a solvent such as propylene carbonate which is known to

increase the adsorptive capability of the clay for organic materials.

The organophilic clay used in the method of the invention can also be incorporated into a garment, such as a
5 diaper, that may come into contact with feces. Fecal enzymes coming into contact with the organophilic clay on the diaper will be inactivated and consequently unavailable to cause irritation to the skin adjacent to the garment. The organophilic clays can be incorporated into a garment such as
10 a diaper by applying them as a coating on the fibers of the garment or as a coating on the web after the garment is fabricated. The garment can also be impregnated with the organophilic clay, either by dipping in a liquid vehicle in which the organophilic clay is suspended and subsequently
15 removing the vehicle, e.g., by evaporation, or by dusting the garment with the organophilic clay alone or in mixture with a dusting powder vehicle, such as described above.

In a preferred embodiment of a fabric according to the invention which can be made into a garment such as a diaper,
20 an organophilic clay may be incorporated into a superabsorbent polymer and the composition so prepared can be incorporated into a fabric, e.g., a non-woven fabric, by procedures conventionally used to incorporate superabsorbent polymers into such fabrics. Such superabsorbent polymers are
25 well known and comprise, among others, cross-linked polymers of acrylic acid, carboxymethyl cellulose cross-linked with epichlorohydrin, poly amino acids, such as polyaspartic acid, cross-linked with, e.g., lysine, graft polymers of cellulose, e.g., wood pulp, and carboxylic monomers, and the like. The
30 preparation of such superabsorbent monomers is conventional and is generally accomplished by polymerizing the monomers in aqueous solution or suspension in an organic solvent in the presence of a suitable initiator of free-radical polymerization. The organophilic clay can be combined with
35 such a superabsorbent polymer by any means that assures adequate dispersal in the polymer matrix. For example, an

organophilic clay, e.g., quaternium 18 bentonite, can be dispersed as a finely divided suspension in an aqueous suspension of a superabsorbent polymer such as arises in the manufacture of such polymers by polymerization of

5 conventional hydrophilic monomers in aqueous solution or suspension. This dispersion can be accomplished by conventional high-shear mixing. A solid powder containing the organophilic clay dispersed in the superabsorbent polymer can then be prepared by conventional drying procedures such

10 as spray drying, jet drying, or the like. The superabsorbent polymer containing an organophilic clay can be incorporated into fabric suitable for use in absorbent garments such as diapers and the like by conventional procedures. For example the superabsorbent polymer can be coated onto the woven or

15 non-woven fabric or the fibers thereof, or it can be incorporated into pockets in the fabric or between layers of woven or non-woven fabric to form a composite fabric. The superabsorbent polymer can be incorporated into a fabric web by impregnating the web with a solution or suspension of the

20 polymer in water or other suitable vehicle followed by drying the impregnated web. The superabsorbent polymer containing an organophilic clay may also be incorporated into a foam layer, e.g., a polyurethane foam layer which is then fixed to a fabric layer or placed between fabric layers to form a

25 fabric suitable for use in a garment such as a diaper. The superabsorbent polymer containing an organophilic clay can also be incorporated into a non-woven fabric by suspending the polymer in finely divided form in a suspension of the precursor fibers, and then forming the non-woven web by a

30 conventional wet-laying method. Diapers made from fabric containing organophilic clay, when worn by infants, can help to prevent skin irritation caused by fecal enzymes.

EXAMPLE

This example illustrates the effectiveness of

35 quaternium-18 bentonite as an adsorbent and deactivator of fecal proteolytic enzymes.

Tests were conducted on solutions of three proteolytic digestive enzymes, chymotrypsin, trypsin and elastase, to demonstrate the effectiveness of a bentonite clay rendered organophilic by treatment with quaternium 18 (hereinafter referred to as "quaternium 18 bentonite" and "Q-18B") in adsorbing and/or deactivating these enzymes. The amount of enzyme immobilized by adsorption onto the Q-18B was determined by high pressure liquid chromatography (HPLC), and the denaturing effect of the Q-18B was determined by measuring the loss of enzyme activity in standard activity tests and comparing the loss in activity with the loss of activity due to sequestration of the enzyme by adsorption.

In order to conduct the tests determining the adsorption and inactivating effectiveness of Q-18B, aqueous solutions of chymotrypsin, trypsin and elastase were prepared in a phosphate buffer at pH 8, a pH at which these enzymes have been shown to have maximum proteolytic activity. The test solutions contained 0.4 milligrams per milliliter (mg/ml) of chymotrypsin, 0.2 mg/ml of trypsin and 1.0 mg/ml of elastase, respectively. These respective concentrations represent the average infant fecal concentrations of these three principal fecal proteolytic enzymes.

The total amount of enzymatic activity in each solution was measured using 1.0 ml aliquots of each solution, using triplicate experiments and taking an average of the three measured values.

The adsorptive and inactivating effect of Q-18B on each of the enzymes in solution was determined by the following procedure. Test samples comprising 10.0 ml of the enzyme solutions were prepared for each enzyme. To each test sample was added 1.0 gram of Q-18B, and the mixture was mixed with a magnetic stirrer for 10 minutes at low speed. The mixture was then filtered through a prewashed No.1 filter paper and the filtrate was collected and its volume measured carefully. A corresponding control sample was prepared by filtering 10 ml of the enzyme solution through a filter paper. The

filtrate was then transferred to a dialysis tube having a dialysis cutoff of 2000 daltons, and dialysis was carried out for 4 hours at 4°-6°C against deionized water. The retentate from the dialysis step was lyophilized to yield a residual enzyme powder. A known weight of the recovered enzyme was dissolved in a phosphate buffer at pH 8 and the enzyme activity was determined as described above. Because the test procedure itself caused some loss of enzyme and of enzymatic activity, a control was run by dissolving another aliquot of the lyophilized recovered enzyme in an appropriate mobile phase and measuring the amount of enzyme by high pressure liquid chromatography (HPLC). The adsorption and inactivating effect of the Q-18B were assessed by comparing the loss in enzyme and enzymatic activity of the treated test samples with the loss observed for the control samples.

The details of the analytical procedures and the results obtained are described below.

In order to prepare samples for analysis of amount of protein and enzyme activity, the lyophilized retentate was dissolved in 6.0 ml of water and divided into two 3.0 ml portions. These solutions were again lyophilized to yield solid residues. Thus each experimental determination gave two residues of equal weight which could be used for determining the amount of protein and the enzymatic activity of the enzyme remaining in the enzyme solutions after treatment with Q-18B.

Determination of amount of enzyme as protein:

Chymotrypsin:

A standard chymotrypsin solution was prepared by dissolving 2.30 mg of chymotrypsin in 2.30 ml of water to give a solution having an enzyme concentration of 1.0 mg/ml.

An amount of 50 microliters (μ l) of this solution was injected into a high performance liquid chromatograph using a Progel TSK Butyl-NPR column with gradient elution using a mobile phase having an initial composition of 2.3 M ammonium

sulfate in a pH 8 phosphate buffer and a final composition of plain phosphate buffer, with a gradient time of 10 minutes. The retention time was determined to be 6.1-6.2 minutes.

5 The lyophilized residues of the control and test samples were each dissolved in 2.0 ml of water, and each of the solutions was filtered through a ball of prewashed cotton and subjected to HPLC using the above protocol. The results of the determinations are summarized in Table 1 below.

10 Trypsin:

A standard trypsin solution was prepared by dissolving 2.50 mg of trypsin in 2.50 ml of water to give a solution having an enzyme concentration of 1.0 mg/ml. An amount of 50 microliters (μ l) of this solution was injected into a high performance liquid chromatograph using a Progel TSK Butyl-NPR column with gradient elution using a mobile phase having an initial composition of 2 M ammonium sulfate in a Tris HCl buffer, pH 7.5, and a final composition of plain buffer devoid of ammonium sulfate, with a gradient time of 15 10 minutes. The retention time was determined to be 20 6.61 minutes for beta-trypsin and 7.72 minutes for alpha-trypsin.

The lyophilized residues of the control and test samples were each dissolved in 2.0 ml of water, and each of the 25 solutions was filtered through a ball of prewashed cotton and subjected to HPLC using the above protocol. The results of the determinations are summarized in Table 1 below, wherein the total concentration of trypsin (alpha- and beta-) is given.

30

Elastase:

A standard elastase solution was prepared by dissolving 1.90 mg of elastase in 0.95 ml of water to give a solution having an enzyme concentration of 2.0 mg/ml. An amount of 35 50-microliters (μ l) of this solution was injected into a high performance liquid chromatograph using a Progel TSK Butyl-NPR

column with gradient elution using a mobile phase having an initial composition of 2 M ammonium sulfate in a Tris HCl buffer, pH 7.5, and a final composition of plain buffer devoid of ammonium sulfate, with a gradient time of 10 minutes. The retention time was determined to be 7.75 minutes.

The lyophilized residues of the control and test samples were each dissolved in 2.0 ml of water, and each of the solutions was filtered through a ball of prewashed cotton and subjected to HPLC using the above protocol. The results of the determinations are summarized in Table 1 below

Table 1
Loss of Enzyme Protein from Solution by Treatment with Q-18

Enzyme	Theoretical amount (mg)	Control		Test sample	
		Amount recovered (mg)	Percent loss	Amount recovered (mg)	Percent loss
Chymo-trypsin	2.0	1.54047	22.98	0.25687	87.16
Trypsin	1.0	1.10293	0	undetectable	90
Elastase	5.0	0.8867	82.23	0.38767	92.25

Determination of enzyme activity:

15 Chymotrypsin:

A standard chymotrypsin solution was prepared by dissolving 0.40 mg of chymotrypsin in 5.0 ml of phosphate buffer. The enzyme concentration was analyzed by the following protocol:

20 Reagents were prepared as follows:

Reagent A: 80 mM Tris HCl buffer, pH 7.8 at 25°C;

Reagent B: 1.18 mM sodium benzoyl tyrosine ethyl ester solution; prepared by initially dissolving the reagent in 31.7 ml of methanol and diluting to a volume of 50 ml with deionized water;

25

BEST AVAILABLE COPY

Reagent C: 1 mM hydrochloric acid solution;

Reagent D: phosphate buffer (The chymotrypsin enzyme solution was used at a concentration of 2-5 units/ml in reagent D.)

5 A reaction solution was prepared by mixing 1.42 ml of Reagent A, 1.40 ml of Reagent B, and 0.08 ml of Reagent C. The solution was mixed by inversion and the optical absorbance at a wavelength of 256 nm ($A_{256\text{nm}}$) was monitored until it was constant. Thereupon 0.1 ml of the enzyme
10 solution in Reagent D was added to the reaction solution, the solutions were mixed by inversion and the $A_{256\text{nm}}$ was monitored for approximately 5 minutes. The maximum rate of increase of optical absorbance ($\Delta A_{256\text{nm}}/\text{min}$) was taken as the measure of enzyme concentration. A blank was run using only Reagent D
15 without enzyme and the $\Delta A_{256\text{nm}}/\text{min}$ for the blank was subtracted from that for the enzyme solution to yield a value proportional to the concentration of the enzyme.

Test samples were analyzed by dissolving the lyophilized residue from the divided dialysis retentate, containing a
20 maximum of 2.0 mg of chymotrypsin, in 5.0 ml of Reagent D, and determining the actual concentration of chymotrypsin by the above-described protocol using 0.1 ml of the solution. The results of the testing are presented in Table 2 below.

25 Trypsin:

A standard trypsin solution was prepared by dissolving 0.40 mg of trypsin in 10.0 ml of phosphate buffer solution (cold). The enzyme concentration was analyzed by the following protocol:

30 Reagents were prepared as follows:

Reagent E: 67 mM sodium phosphate buffer, pH 7.6 at 25°C;

Reagent F: 0.25 mM sodium benzoyl L-arginine ethyl ester solution;

35 Reagent G: trypsin enzyme solution containing 350-700 units/ml in Reagent E.

A reaction solution was prepared by equilibrating 3.00 ml of Reagent E at 25°C and the optical absorbance at a wavelength of 253 nm ($A_{253\text{nm}}$) was monitored until it was constant. Thereupon 0.2 ml of Reagent G was added to the
5 reaction solution, the solutions were mixed by inversion and the $A_{253\text{nm}}$ was monitored for approximately 5 minutes. The maximum rate of increase of optical absorbance ($\Delta A_{256\text{nm}}/\text{min}$) was taken as the measure of enzyme concentration. A blank was run using Reagent G without enzyme and the $\Delta A_{256\text{nm}}/\text{min}$ for
10 the blank was subtracted from that for the enzyme solution to yield a value proportional to the concentration of the enzyme.

Test samples were analyzed by dissolving the lyophilized residue from the divided dialysis retentate, containing a
15 maximum of 1.0 mg of chymotrypsin, in 10.0 ml of Reagent E, and determining the actual concentration of chymotrypsin by the above-described protocol using 0.2 ml of the sample solution. The results of the tests are presented in Table 2 below.

20

Elastase:

An end-point colorimetric method was used to determine the amount of elastase in the test samples, i.e., the lyophilized residue of the divided dialysis retentate.

25

Reagents were prepared as follows:

Reagent H: 200 mM Tris buffer, pH 8.8 at 37°;

Reagent I: elastase-orcein substrate;

Reagent J: elastase enzyme solution containing 25-100 units/ml in Reagent H.

30

A series of elastase substrate solutions was prepared by dissolving weighed amounts of Reagent I in Reagent H. A quantity of the standard or test solution was then mixed with the substrate solutions as follows:

Solutions/ reagent	Std.1	Std.2	Std.3	Std.4	Std.5	Std. Blank
Reagent I (mg)	1.0	2.0	4.0	8.0	16.0	0.00
Reagent H (ml)	6.00	6.00	6.00	6.00	6.00	6.00

5

A standard solution of elastase was prepared by dissolving 12.06 mg of elastase in 2.0 ml of buffer to give a solution having 1.03 mg of elastase per milliliter. A quantity of 0.01 ml of the standard elastase solution was added to the substrate solutions, and the solution was mixed by swirling and incubated for 12-16 hours at 37°C. The optical density at a wavelength of 590 nanometers (A_{590}) of the standards was measured and a standard curve was prepared.

Test samples were analyzed by dissolving the lyophilized residue from the divided dialysis retentate, containing a maximum of 5.0 mg (600 units) of elastase, in 2.0 ml of buffer, and incubating 0.01 ml of the test solutions with substrate mixture for 20 minutes at 37°C. The A_{590} was measured for the test samples and the standard solution prepared by the above protocol, and the amount of enzyme was calculated. The results of the determination are presented in Table 2 below.

Table 2

Loss of Enzyme Protein from Solution by Treatment with Q-18B

Enzyme	Theoretical amount (units)	Control		Test sample	
		Amount recovered (units)	Percent loss	Amount recovered (units)	Percent loss
Chymo- trypsin	104	47.4	54.42	6.29	93.94
Trypsin	8060	5467	32.17	782.5	90.3
Elastase	350	158.2	54.8	135.5	61.29

The data presented in the example illustrate that a substantial fraction of the proteolytic fecal enzymes

responsible for the skin irritation of diaper rash and the like are inactivated by contact with organophilic clays such as quaternium-18 bentonite.

5 The invention having now been fully described, it should be understood that it may be embodied in other specific forms or variations without departing from its spirit or essential characteristics. Accordingly, the embodiments described above are to be considered in all respects as illustrative and not restrictive, the scope of the invention being
10 indicated by the appended claims rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

I CLAIM:

1. A method for protecting skin of humans and mammals from irritation caused by contact with feces containing proteolytic enzymes comprising contacting feces containing proteolytic enzymes capable of irritating skin that comes into contact with said feces with an amount of an organophilic clay sufficient to substantially reduce skin-irritating activity of said proteolytic enzymes.
2. The method of Claim 1 comprising applying said organophilic clay to said skin.
3. The method of Claim 2 comprising applying said organophilic clay is applied to said skin in a pharmaceutically acceptable dermatological vehicle.
4. The method of Claim 3 wherein said vehicle is a lotion.
5. The method of Claim 3 wherein said vehicle is a gel.
6. The method of Claim 3 wherein said vehicle is a cream.
7. The method of Claim 3 wherein said vehicle is a dusting powder.
8. The method of Claim 1 wherein said organophilic clay is a reaction product of a clay selected from the group consisting of naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite and stevensite, and their synthetically produced analogs, with a long chain organic quaternary ammonium compound.
9. The composition of Claim 8 wherein said organophilic clay is activated.

10. The method of Claim 8 wherein said organophilic clay is a reaction product of bentonite with a long chain organic quaternary ammonium compound.
- 5 11. The method of Claim 10 wherein said organophilic clay is activated.
12. The method of Claim 10 wherein said organophilic clay is quaternium 18 bentonite.
- 10 13. The method of Claim 12 wherein said quaternium 18 bentonite is activated.
14. A composition for protecting the skin against the skin-irritating activity of proteolytic enzymes found in feces comprising an organophilic clay dispersed in a pharmaceutically acceptable dermatological vehicle.
- 15 15. The composition of Claim 14 wherein said organophilic clay is present in an amount of about 3 % to about 50 % by weight.
- 20 16. The composition of Claim 15 wherein said organophilic clay is present in an amount of about 3% by weight to about 20 % by weight.
- 25 17. The composition of Claim 15 wherein said organophilic clay is present in an amount of about 3% by weight to about 10 % by weight.
- 30 18. The composition of Claim 14 wherein said organophilic clay is a reaction product of a clay selected from the group consisting of naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite and stevensite, and their synthetically produced analogs, with a long chain organic quaternary ammonium compound.
- 35

19. The composition of Claim 18 wherein said organophilic clay is activated.

5 20. The composition of Claim 18 wherein said organophilic clay is a reaction product of bentonite with a long chain organic quaternary ammonium compound.

10 21. The composition of Claim 20 wherein said organophilic clay is activated.

22. The composition of Claim 20 wherein said organophilic clay is quaternium 18 bentonite.

15 23. The composition of Claim 22 wherein said quaternium 18 bentonite is activated.

20 24. A solid composition comprising an organophilic clay dispersed in a water-permeable matrix.

25 25. The composition of Claim 24 wherein said matrix is a superabsorbent polymer.

26. The composition of Claim 25 wherein said superabsorbent polymer is a cross-linked polymer of an unsaturated carboxylic acid.

30 27. The composition of Claim 26 wherein said unsaturated carboxylic acid is acrylic acid.

28. The composition of Claim 25 wherein said superabsorbent polymer is a cross-linked polymer of an amino acid.

35 29. The composition of Claim 28 wherein said amino acid is aspartic acid.

30. The composition of Claim 24 wherein said organophilic clay is present in an amount of about 3 % to about 50 % by weight.

5 31. The composition of Claim 24 wherein said organophilic clay is present in an amount of about 3% by weight to about 20 % by weight.

10 32. The composition of Claim 24 wherein said organophilic clay is present in an amount of about 3% by weight to about 10 % by weight.

15 33. The composition of Claim 24 wherein said organophilic clay is a reaction product of a clay selected from the group consisting of naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite and stevensite, and their synthetically produced analogs, with a long chain organic quaternary ammonium compound.

20 34. The composition of Claim 33 wherein said organophilic clay is activated.

25 35. The composition of Claim 33 wherein said organophilic clay is a reaction product of bentonite with a long chain organic quaternary ammonium compound.

36. The composition of Claim 35 wherein said organophilic clay is activated.

30 37. The composition of Claim 35 wherein said organophilic clay is quaternium 18 bentonite.

35 38. The composition of Claim 37 wherein said quaternium 18 bentonite is activated.

39. A fabric comprising a woven or non-woven web having incorporated therein an organophilic clay.

40. The fabric of Claim 39 wherein said organophilic clay is dispersed in a water-permeable matrix.

41. The fabric of Claim 40 wherein said matrix is a superabsorbent polymer.

42. The fabric of Claim 41 wherein said superabsorbent polymer is a cross-linked polymer of an unsaturated carboxylic acid.

43. The fabric of Claim 42 wherein said unsaturated carboxylic acid is acrylic acid.

44. The fabric of Claim 41 wherein said superabsorbent polymer is a cross-linked polymer of an amino acid.

45. The fabric of Claim 44 wherein said amino acid is aspartic acid.

46. The fabric of Claim 41 wherein said organophilic clay is present in an amount of about 3 % to about 50 % by weight.

47. The fabric of Claim 41 wherein said organophilic clay is present in an amount of about 3% by weight to about 20 % by weight.

48. The fabric of Claim 41 wherein said organophilic clay is present in an amount of about 3% by weight to about 10 % by weight.

49. The fabric of Claim 41 wherein said organophilic clay is a reaction product of a clay selected from the group consisting of naturally occurring montmorillonite, bentonite,

beidellite, hectorite, saponite and stevensite, and their synthetically produced analogs, with a long chain organic quaternary ammonium compound.

5 50. The fabric of Claim 49 wherein said organophilic clay is activated.

51. The fabric of Claim 49 wherein said organophilic clay is a reaction product of bentonite with a long chain organic
10 quaternary ammonium compound.

52. The fabric of Claim 51 wherein said organophilic clay is activated.

15 53. The fabric of Claim 51 wherein said organophilic clay is quaternium 18 bentonite.

54. The fabric of Claim 53 wherein said quaternium 18 bentonite is activated.
20

55. A garment made from a fabric comprising a woven or non-woven web having incorporated therein an organophilic clay.

56. The garment of Claim 55 wherein said organophilic clay
25 is dispersed in a water-permeable matrix.

57. The garment of Claim 56 wherein said matrix is a superabsorbent polymer.

30 58. The garment of Claim 57 wherein said garment is a diaper.

59. The diaper of Claim 58 wherein said superabsorbent polymer is a cross-linked polymer of an unsaturated
35 carboxylic acid.

60. The diaper of Claim 59 wherein said unsaturated carboxylic acid is acrylic acid.

61. The diaper of Claim 58 wherein said superabsorbent
5 polymer is a cross-linked polymer of an amino acid.

62. The diaper of Claim 61 wherein said amino acid is aspartic acid.

10 63. The diaper of Claim 58 wherein said organophilic clay is present in said matrix in an amount of about 3 % to about 50 % by weight.

15 64. The diaper of Claim 58 wherein said organophilic clay is present in said matrix in an amount of about 3% by weight to about 20 % by weight.

20 65. The diaper of Claim 58 wherein said organophilic clay is present in said matrix in an amount of about 3% by weight to about 10 % by weight.

25 66. The diaper of Claim 58 wherein said organophilic clay is a reaction product of a clay selected from the group consisting of naturally occurring montmorillonite, bentonite, beidellite, hectorite, saponite and stevensite, and their synthetically produced analogs, with a long chain organic quaternary ammonium compound.

30 67. The diaper of Claim 66 wherein said organophilic clay is activated.

35 68. The diaper of Claim 66 wherein said organophilic clay is a reaction product of bentonite with a long chain organic quaternary ammonium compound.

69. The diaper of Claim 68 wherein said organophilic clay is activated.

5 70. The diaper of Claim 68 wherein said organophilic clay is quaternium 18 bentonite.

71. The diaper of Claim 70 wherein said quaternium 18 bentonite is activated.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05848

A. CLASSIFICATION OF SUBJECT MATTER				
IPC(6) :A61L 15/18 US CL :424/76.6, 443 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/76.6				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 2,883,356 A (GLUESENKAMP) 21 April 1959, columns 10-12.	1-71		
Y	US 3,208,984 A (DEKKING) 28 September 1965, see columns 3-6.	1-71		
Y	US 4,707,293 A (FERRO) 17 November 1987, see columns 3-6.	1-71		
Y	US 4,450,151 A (SHINOZAWA) 22 May 1984, see working examples.	1-71		
Y	US 4,861,584 A (POWELL, JR. et al) 29 August 1989, see entire document.	1-71		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
* Special categories of cited documents: <table border="0" style="width:100%"> <tr> <td style="width:50%"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width:50%"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *G* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *G* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *G* document member of the same patent family			
Date of the actual completion of the international search 19 JUNE 1997		Date of mailing of the international search report 11 JUL 1997		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer PETER KULKOSKY Telephone No. (703) 308-2351		

Form PCT/ISA/210 (second sheet)(July 1992)*

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)